Century Therapeutics (NASDAQ:IPSC) Downgraded to Sell Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Century Therapeutics (NASDAQ:IPSC) from "hold" to a sell rating; overall analyst mix is mixed (four Buys, two Holds, one Sell) with an average price target of $4.25.
• The stock trades around $2.22 with a market cap near $400M and negative EPS (last quarter -$0.25, consensus -0.63 for the year) after a slight beat versus estimates.
• Shareholder concerns include insider selling and a reported ~134% dilutive PIPE

Century Therapeutics (NASDAQ:IPSC - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday.

Several other research analysts also recently commented on the stock. Leerink Partners set a $2.00 price objective on shares of Century Therapeutics and gave the company a "market perform" rating in a research report on Friday, March 13th. TD Cowen began coverage on shares of Century Therapeutics in a report on Wednesday, February 25th. They set a "buy" rating for the company. HC Wainwright boosted their price objective on shares of Century Therapeutics from $2.00 to $5.00 and gave the stock a "buy" rating in a research note on Tuesday. Piper Sandler boosted their price objective on shares of Century Therapeutics from $2.00 to $4.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 20th. Finally, Zacks Research cut shares of Century Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, March 12th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $4.25.

Century Therapeutics Stock Down 1.8%

Shares of NASDAQ:IPSC opened at $2.22 on Friday. Century Therapeutics has a 12-month low of $0.44 and a 12-month high of $3.04. The business has a 50 day moving average of $2.30 and a 200-day moving average of $1.48. The stock has a market cap of $399.73 million, a PE ratio of -15.86 and a beta of 1.66.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.04. Equities research analysts expect that Century Therapeutics will post -0.63 earnings per share for the current year.

Insider Buying and Selling at Century Therapeutics

In related news, insider Gregory Russotti sold 10,076 shares of the company's stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $2.55, for a total value of $25,693.80. Following the sale, the insider owned 515,427 shares in the company, valued at $1,314,338.85. This represents a 1.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 17,921 shares of company stock worth $45,458 in the last quarter. 4.37% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Century Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Prudential Financial Inc. purchased a new stake in Century Therapeutics in the 2nd quarter valued at about $25,000. Qube Research & Technologies Ltd purchased a new stake in Century Therapeutics in the 2nd quarter valued at about $38,000. Raymond James Financial Inc. bought a new position in shares of Century Therapeutics during the 2nd quarter valued at approximately $51,000. AQR Capital Management LLC grew its position in shares of Century Therapeutics by 358.9% during the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company's stock valued at $53,000 after acquiring an additional 86,875 shares during the period. Finally, Bank of America Corp DE grew its position in shares of Century Therapeutics by 109.1% during the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company's stock valued at $67,000 after acquiring an additional 34,466 shares during the period. Institutional investors and hedge funds own 50.20% of the company's stock.

Key Century Therapeutics News

Here are the key news stories impacting Century Therapeutics this week:

• Positive Sentiment: Seeking Alpha publishes a speculative Buy thesis highlighting Century’s pivot to autoimmune CAR cells and CNTY‑813 (Type 1 diabetes) as the main value driver; the piece also notes management cut quarterly cash burn (from ~$35M to ~$20M) and extended runway to Q1 2028 — positive for execution and optionality. Century Therapeutics: A Biotech With Interesting Optionality Opportunities
• Positive Sentiment: HC Wainwright reiterated a Buy rating and $5 price target and published detailed EPS trajectories showing multi‑year losses but continued coverage — an analyst endorsement that can support the stock if pipeline milestones progress. MarketBeat: Century Therapeutics analyst coverage
• Neutral Sentiment: Short‑interest report shows effectively zero reported short interest and a 0.0 days‑to‑cover — likely a data artifact or low reported shorting activity; not a clear signal for immediate directional pressure.
• Negative Sentiment: Seeking Alpha and company disclosures note a materially dilutive PIPE (cited as ~134% dilution) — significant dilution can weigh on the stock and caps upside until the market sees meaningful clinical progress or revenue potential. Century Therapeutics: A Biotech With Interesting Optionality Opportunities

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company's proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.